Clinical implication of EZH2 inhibitors in hepatocellular carcinoma

被引：0
|
作者：
Sohn, Bo Hwa
Lee, Sung Hwan
Jeong, Yun Seong
Lee, Ju-Seog
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6139
引用
收藏
页数：2
相关论文
共 50 条
  • [1] DNMT AND EZH2 INHIBITORS SYNERGIZE TO ACTIVATE THERAPEUTIC TARGETS IN HEPATOCELLULAR CARCINOMA
    Zhang, Lian
    Li, Hongtao
    Lu, Qianjin
    Weisenberger, Dan
    O'Connell, Casey
    Machida, Keigo
    An, Woojin
    Lenz, Heinz-Josef
    El-Khoueiry, Anthony
    Jones, Peter A.
    Liu, Minmin
    Liang, Gangning
    HEPATOLOGY, 2022, 76 : S1248 - S1249
  • [2] DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma
    Zhang, Lian
    Li, Hong -Tao
    Shereda, Rachel
    Lu, Qianjin
    Weisenberger, Daniel J.
    O'Connell, Casey
    Machida, Keigo
    An, Woojin
    Lenz, Heinz-Josef
    El-Khoueiry, Anthony
    Jones, Peter A.
    Liu, Minmin
    Liang, Gangning
    CANCER LETTERS, 2022, 548
  • [3] Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy
    Bae, An-Na
    Jung, Soo-Jung
    Lee, Jae-Ho
    Lee, Hyunsu
    Park, Seung Gyu
    MEDICINA-LITHUANIA, 2022, 58 (02):
  • [4] Oncogenic deregulation of the methyltransferase EZH2 in hepatocellular carcinoma
    Bae, W. K.
    Ik-Joo, C.
    Kang, K.
    Hennighausen, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S88 - S88
  • [5] The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma
    Gao, Shu-Bin
    Xu, Bin
    Ding, Li-Hong
    Zheng, Qi-Lin
    Zhang, Li
    Zheng, Qi-Fan
    Li, Shan-Hua
    Feng, Zi-Jie
    Wei, Jie
    Yin, Zhen-Yu
    Hua, Xianxin
    Jin, Guang-Hui
    JOURNAL OF HEPATOLOGY, 2014, 61 (04) : 832 - 839
  • [6] The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
    Wu, Shi-yi
    Xie, Zhao-yu
    Yan, Lu-yu
    Liu, Xiao-fang
    Zhang, Yue
    Wang, Da-an
    Dong, Jie
    Sun, Hong-tao
    BMC IMMUNOLOGY, 2022, 23 (01)
  • [7] The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
    Shi-yi Wu
    Zhao-yu Xie
    Lu-yu Yan
    Xiao-fang Liu
    Yue Zhang
    Da-an Wang
    Jie Dong
    Hong-tao Sun
    BMC Immunology, 23
  • [8] EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma
    Guo, Baoping
    Tan, Xiaohong
    Cen, Hong
    PLOS ONE, 2020, 15 (11):
  • [9] EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
    Wang, Bohan
    Liu, Yachong
    Liao, Zhibin
    Wu, Haofeng
    Zhang, Bixiang
    Zhang, Lei
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [10] Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma
    Yu, Yung-Luen
    Su, Kuo-Jung
    Hsieh, Yi-Hsien
    Lee, Hsiang-Lin
    Chen, Tzy-Yen
    Hsiao, Pei-Ching
    Yang, Shun-Fa
    PLOS ONE, 2013, 8 (09):
12345